ESR1 and breast cancer: PD-L1 displayed lower positivity in immune cells in ER+ BC than TNBC (median = 1% vs. 20%; p = 0.011), whereas the PD-L2-positivity in cancer cells or immune cells did not differ significantly between ER+ BC and TNBC.